Since its establishment in 1967, GC Pharma has been safeguarding the public health of S. Korea and is now becoming a leader in the global health industry through its focus on developing necessary, but difficult-to-make medicines. In 1971, GC Pharma (formerly known as Green Cross Corporation) became the first company in S.Korea and the sixth company in the world to establish a plasma fractionation plant. In 2009, it completed the construction of the Ochang Plant, the largest biotech facility at the time. GC Pharma has been producing and exporting a variety of plasma-derived products, including albumin, immunoglobulin, and antithrombin.
Prevention of disease is another priority at GC Pharma. In 1983, the company became the third in the world to develop a hepatitis-B vaccine; followed by in 1988 becoming the first in the world to develop a vaccine against the Hantavirus hemorrhagic fever. In 1993, GC Pharma became the second in the world to develop a varicella vaccine, and in 2015 it became the fourth in the world to develop a quadrivalent flu vaccine (GC Flu Quadrivalent), thereby establishing itself as a world-class. leader in vaccine development.